Error loading player: No playable sources found

89836

Plenary Session 1 - Genetic Modification Technologies for Cell-based Gene Therapies

Date
June 11, 2024
This product is not available for individual purchase, but it is available as part of the following products:

In addition to the now well-known CAR T (chimeric antigen receptor T cells) and HSC (CD34+ hematopoietic stem cells) cell-based gene therapies, there are several other modes of gene modification as well as cell types already approved and on the horizon. CAR T and HSC genetically engineered therapeutics have typically relied upon lentiviral or gamma-retroviral vector transduction to introduce gene(s) of interest but other methods of gene modification can introduce, replace or inactivate genes in the cells of interest. Recently approved CASGEVY is the first approved therapy to rely on CRISPR/Cas9 gene-editing to modify HSCs. More complex genetically engineered cell therapies may require inclusion of multiple modes of gene modification in the same cell to ensure the desired product attributes. Challenges include effective delivery methods, effective targeting, effective cell selection and expansion, and development of appropriate analytical methods to assess more complex and novel genetic engineering approaches.   



Session Speakers:


Ingenui-T, a Rapid Autologous Chimeric Antigen Receptor (CAR)-T Manufacturing Solution Using Whole Blood, for Treatment of Autoimmune Disease

Sunetra Biswas, Kyverna Therapeutics, Inc.


CMC Development of PM359, a Prime Edited Hematopoietic Stem Cell Therapy for the Treatment of P47phox-Deficient Chronic Granulomatous Disease (CGD)

Barrett NehillaPrime Medicine, Inc.


Enabling the Advancement of Cell Therapies with Epigenetic Editing

Nathan YeeTune Therapeutics



Additional Panelist:


Zhaohui Ye, CBER, FDA


Related Products

Thumbnail for Plenary Session 8 - Global Regulatory Updates and Panel Discussion & Closing Remarks
Plenary Session 8 - Global Regulatory Updates and Panel Discussion & Closing Remarks
The cell and gene therapy field spans an enormous range of product types and technologies with the potential to provide curative treatments for a wide range of serious diseases…
Thumbnail for Parallel Session 3 - Viral Vector-based Gene Therapy Products
Parallel Session 3 - Viral Vector-based Gene Therapy Products
The field of Cell and Gene Therapy has witnessed expanding numbers of regulatory approvals in recent years…
Thumbnail for Plenary Session 7 - Streamlining AAV Vector-based Gene Therapy Development Through the Utilization of Manufacturing and Analytical Platform Approaches
Plenary Session 7 - Streamlining AAV Vector-based Gene Therapy Development Through the Utilization of Manufacturing and Analytical Platform Approaches
Our ability to treat diseases previously untreatable through the delivery of adeno-associated virus (AAV)-based gene therapies has been a tremendous advancement in pharmaceutical development…
Thumbnail for Hot Topic Session - ICH Cell & Gene Therapy Discussion Group Updates
Hot Topic Session - ICH Cell & Gene Therapy Discussion Group Updates
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) brings together regulatory authorities and representatives from the pharmaceutical industry from across the globe to discuss a range of technical and scientific considerations for medicinal…